The Journal of dermatological treatment最新文献

{"title":"Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study - IL PSO (Italian Landscape Psoriasis).","authors":"D Orsini, D Graceffa, M Burlando, A Campanati, E Campione, C Guarneri, A Narcisi, P Pella, P Romita, M Travaglini, L Zichichi, L M H Arancio, G Baggini, R Balestri, L Bianchi, A M G Brunasso, A E Cagni, Giacomo Caldarola, G Calianno, A Carpentieri, M Carriero, A Carugno, F Cona, A Costanzo, E Cozzani, Giacomo Dal Bello, Giovanni Carlo Lazzaro Danzuso, A Dattola, A Di Tano, F Diotallevi, M Donnarumma, E De Col, M Esposito, C S Fiorella, M Galluzzo, F Graziola, M Licciardello, A Legori, P Malagoli, Federica Mola, G Moretta, A Muracchioli, A Musumeci, M L Musumeci, G Pagnanelli, V Panasiti, E Provenzano, D Rizzo, M Rubatto, Oriele Sarno, D Strippoli, F Vaira, M C Fargnoli","doi":"10.1080/09546634.2025.2452948","DOIUrl":"https://doi.org/10.1080/09546634.2025.2452948","url":null,"abstract":"","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2452948"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tofacitinib as a promising treatment for refractory erythroderma-like Hailey-Hailey disease.","authors":"Huaye Bao, Keyi Yu, Feilong An, Xin-Gang Wu","doi":"10.1080/09546634.2025.2493936","DOIUrl":"https://doi.org/10.1080/09546634.2025.2493936","url":null,"abstract":"<p><strong>Purpose: </strong>Hailey-Hailey disease (HHD), a rare autosomal dominant blistering disorder predominantly affecting intertriginous areas, is characterized by chronic relapsing courses that cause substantial morbidity. Despite multiple available therapeutic modalities, management of refractory cases remains challenging.</p><p><strong>Materials and methods: </strong>This case report details a 67-year-old male with severe erythroderma-like HHD, whose genetic analysis revealed a heterozygous nonsense mutation (c.1774C > T) in the <i>ATP2C1</i> gene. Following conventional therapies, the patient developed treatment-related complications. Therefore, oral tofacitinib was administered as an alternative treatment.</p><p><strong>Results: </strong>The patient achieved marked clinical improvement post-tofacitinib administration, with no treatment-emergent adverse events.</p><p><strong>Conclusions: </strong>This case indicates that tofacitinib may serve as a promising therapeutic option for refractory erythroderma-like HHD, particularly in cases linked to <i>ATP2C1</i> mutations.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2493936"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144048065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The evolving landscape for vitiligo management.","authors":"Alishba Zainab","doi":"10.1080/09546634.2025.2498581","DOIUrl":"https://doi.org/10.1080/09546634.2025.2498581","url":null,"abstract":"","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2498581"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144045621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can pimozide kill parasites? Surprisingly, the most honest answer is 'yes'.","authors":"Georgia Marquez-Grap, Allison Kranyak, Nicholas Brownstone, John Koo","doi":"10.1080/09546634.2025.2466635","DOIUrl":"10.1080/09546634.2025.2466635","url":null,"abstract":"<p><p><b>Purpose:</b> One of the most well-known medications for treating delusional infestation (DI) is pimozide. Many patients may be reluctant to initiate treatment unless a medication has anti-pathogenic properties, as they feel otherwise it does not address their concerns regarding infestation. In this article, we explore the evidence that pimozide has a range of antipathogenic effects and how this fact can aid in patient care.</p><p><p><b>Materials and methods:</b> A scoping literature review was performed using The National Library of Medicine (PubMed). The search terms used were pimozide AND anti-microbial OR anti-bacterial OR anti-infective. All relevant articles were reviewed up to September 2024.</p><p><p><b>Results:</b> Our findings show that pimozide has antibacterial and antiparasitic effects through several unique mechanisms. Additionally, several older first-generation antipsychotics also have demonstrated anti-pathogenic properties. While the studies identified are entirely <i>in vitro</i>, the potential antipathogenic effects of pimozide may be pivotal to patients with DI as they make the critical decision to accept or reject treatment.</p><p><p><b>Conclusion:</b> With adequate disclaimers that pimozide's therapeutic efficacy may not have to do with its anti-pathogen profile, the evidence that pimozide has anti-pathogenic properties may enable dermatology providers to strengthen their therapeutic approach and alliance with patients with DI and make life-changing therapy more acceptable to the patient.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2466635"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143485223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of topical antimicrobial-corticosteroid combination therapy in comparison to topical steroids alone on the skin microbiome of patients with atopic dermatitis.","authors":"Li Tingting, Peixin Zhang, Li Yang, Ruoyu Li, Ruojun Wang","doi":"10.1080/09546634.2025.2470379","DOIUrl":"10.1080/09546634.2025.2470379","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to analyze the different therapeutic responses between topical antimicrobial-corticosteroid combination and topical corticosteroids alone on improving the skin microbiome and skin barrier of patients with atopic dermatitis (AD).</p><p><strong>Methods: </strong>Forty patients with mild-to-moderate AD were randomly assigned to receive two kinds of treatment. Skin swabs were collected from the lesional sites and nearby nonlesional sites at baseline, after topical medication treatment and 2 weeks post-treatment, and were analyzed by DNA sequencing of the fungal internal transcribed spacer (ITS)1-5 rDNA gene and the V3V4 region of the bacterial 16S rRNA gene.</p><p><strong>Results: </strong>According to our research analysis, both topical steroids alone and combination treatment of steroids and antimicrobials effectively improved the severity of AD and repaired skin barrier. AD lesions were characterized by a decreased sebum level, lower abundance of <i>Cutibacterium</i> and a higher abundance of <i>Staphylococcus</i>. A combined topical treatment with an antimicrobial and steroid showed better responses in increasing skin sebum level and restoring the skin bacterial microbiome, whereas topical steroid alone did not improve skin dysbiosis.</p><p><strong>Conclusion: </strong>A combined therapy with antimicrobial and steroid helps to recover the skin microbiome. Further studies are necessary to explore the therapeutic effects of treatments aiming at balancing the microbiome.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2470379"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143495144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline hair loss severity as a potential confounder in studies on minoxidil and low-level laser therapy.","authors":"Amir Reza Akbari, Benyamin Alam, Ahmed Ageed","doi":"10.1080/09546634.2025.2506673","DOIUrl":"https://doi.org/10.1080/09546634.2025.2506673","url":null,"abstract":"","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2506673"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144113279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interleukin-23p19 inhibitors for the treatment of moderate-to-severe psoriasis: an expert opinion of real-world evidence studies in Europe.","authors":"S Ständer, D Thaçi","doi":"10.1080/09546634.2024.2438803","DOIUrl":"10.1080/09546634.2024.2438803","url":null,"abstract":"<p><p><b>Background:</b> Psoriasis is a chronic inflammatory disease affecting about 2% of the global population, with moderate-to-severe forms requiring systemic treatment for successful disease management. By targeting the interleukin (IL)-23p19 subunit of IL-23, the master cytokine of psoriasis pathogenesis, guselkumab, tildrakizumab, and risankizumab offer improved risk-benefit profiles.</p><p><p><b>Objective:</b> While randomized clinical trials (RCTs) provide controlled data, real-world evidence (RWE) offers insights into the performance of these therapies in diverse patient populations, including those with comorbidities or difficult-to-treat areas affected. With RWE on these inhibitors constantly emerging, a comprehensive overview and expert interpretation are essential for providing key insights into psoriasis management in clinical practice.</p><p><p><b>Methods:</b> This review, therefore, examined RWE on the effectiveness and safety of IL-23p19 inhibitors compared to their pivotal RCTs.</p><p><p><b>Results:</b> Despite some gaps between RCT and RWE outcomes, particularly in underrepresented subpopulations, IL-23p19 inhibitors show strong effectiveness and favorable safety across both settings in the short- and especially in the long term, accompanied by an improvement in health-related quality of life and reduction of the main symptoms.</p><p><p><b>Conclusion:</b> Altogether, these factors make these medicines ideal treatment options. Future research should focus on improving patient-reported outcomes, specifically addressing psychological and quality-of-life aspects, to further optimize psoriasis management.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2438803"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144113281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment goals and preferences of pediatric atopic dermatitis patients, young adults, and caregivers.","authors":"Lisa P van der Rijst, Marjolein S de Bruin-Weller, Nicolaas P A Zuithoff, Saskia Spillekom-van Koulil, Marieke M B Seyger, Marlies de Graaf","doi":"10.1080/09546634.2025.2503273","DOIUrl":"https://doi.org/10.1080/09546634.2025.2503273","url":null,"abstract":"<p><strong>Purpose: </strong>Understanding the treatment goals and preferences of young atopic dermatitis (AD) patients and their caregivers is crucial for enhancing patient-centered care. This study aims to identify these goals and preferences and explore heterogeneity among subgroups.</p><p><strong>Materials and methods: </strong>A web-based survey was conducted among children (6-11 years), adolescents (12-17 years), and young adults (18-30 years) with AD and caregivers of AD patients. Survey questions included multiple-choice, four-point Likert scale, and open-ended questions. Goals and preferences were stratified by age, gender, disease severity, current treatment, visible lesions, and atopic comorbidity.</p><p><strong>Results: </strong>A total of 286 respondents were included. Prioritized treatment goals were 'no itch', 'preventing new lesions', and 'no lesions'. Prioritized treatment characteristics were 'high effectiveness' and 'long-term safety'. Young patients (6-30 years) considered convenience of treatment more important than caregivers, while caregivers considered short- and long-term safety more important than young patients. Pediatric patients (6-17 years) considered psychosocial goals more important than young adults. Goals and preferences also differed by disease severity, gender, current treatment, and atopic comorbidity.</p><p><strong>Conclusions: </strong>Young AD patients and caregivers strive to reduce itch and lesions with effective and safe treatment. Goals and preferences differ within individuals at different stages of life, highlighting the importance of addressing individual needs to improve patient-centered care.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2503273"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144153139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of serious infection with JAK inhibitors in immune-mediated inflammatory skin diseases: a meta-analysis of randomized clinical trials.","authors":"Xinhong Su, Yushan Ou, Shifan Ruan, Xiaoqing Lv, Kun Qin, Jing Mao, Chao Ji","doi":"10.1080/09546634.2025.2474507","DOIUrl":"10.1080/09546634.2025.2474507","url":null,"abstract":"<p><strong>Background: </strong>Emerging research suggests that Janus kinase-signal transducer and activator of transcription (JAK-STAT) inhibitors may be associated with a higher risk of serious infection for patients with rheumatoid arthritis. However, there is no consensus on whether JAK inhibitors increase the risk of serious infection in patients with Immune-mediated inflammatory skin diseases (IMISDs).</p><p><strong>Objectives: </strong>To ascertain the correlation between JAK inhibitor use and the risk of serious infection in patients with IMISDs.</p><p><strong>Methods: </strong>PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), and registered Clinical Trials were searched up to June 1, 2024, using specific search terms related to JAK inhibitors and IMISDs. Randomized clinical trials (RCTs) comparing JAK inhibitors with a control group in patients with IMISDs were included. Studies focusing on cohort studies, case reports, case series, review articles, pooled analysis studies, post hoc analyses and topical JAK inhibitors were excluded. Data were extracted independently by two authors, focusing on serious infections defined according to each study's criteria. Crude numbers for serious infections were pooled and underwent meta-analysis. We assessed the primary outcome regarding the occurrence of severe infections for each study.</p><p><strong>Results: </strong>Thirty-two randomized clinical trials involving 11,917 patients were included. Serious infections were reported in 0.62% of patients receiving JAK inhibitors and 0.51% of controls. Meta-analysis found no significant increase in risk of serious infection (I²=0.00%, RR, 0.68; 95% CI, 0.43-1.07). Subgroup analyses revealed no significant heterogeneity based on condition (<i>p</i> = .56) or medication (<i>p</i> = .69).</p><p><strong>Conclusions: </strong>This meta-analysis demonstrates that JAK inhibitors do not significantly increase the risk of serious infections in IMISD patients compared to control treatments. These findings support the safety of JAK inhibitors in this population. Future research should focus on real-world evidence to further assess their risk-benefit profile in dermatological practice.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2474507"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of a skin management model based on a precision quantitative ointment dispenser on skin symptoms and quality of life in elderly psoriasis patients.","authors":"Jing Shen, Wei Zhou, Hui Zhang, Jiejun Jiang, Wei Dai","doi":"10.1080/09546634.2025.2474505","DOIUrl":"10.1080/09546634.2025.2474505","url":null,"abstract":"<p><strong>Objective: </strong>This study explores the effects of a skin management model based on a precision quantitative ointment dispenser on skin symptoms and quality of life in elderly psoriasis patients.</p><p><strong>Methods: </strong>Elderly psoriasis patients adopted a skin management model based on a precision quantitative ointment dispenser. The Psoriasis Area and Severity Index (PASI) was measured prior to the intervention and at 2, 4, and 6 weeks post-intervention. The Chinese version of the Strategies Used by Patients to Promote Health (C-SUPPH), Symptom Checklist-90 (SCL-90), and Dermatology Life Quality Index (DLQI) were assessed at baseline and after 6 weeks. Patient satisfaction was measured following the 6-week intervention.</p><p><strong>Results: </strong>Both groups demonstrated reductions in PASI scores at 2, 4, and 6 weeks, with the observation group scoring lower (<i>p</i> < 0.05). After 6 weeks, all dimensions of the C-SUPPH showed improvements in both groups, with the observation group exhibiting greater enhancements; SCL-90 scores for anxiety and phobic anxiety reduced in the observation group; DLQI scores decreased in both groups, but the observation group reported superior outcomes; the observation group recorded a higher satisfaction rate (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>The precision quantitative ointment dispenser-based skin management model improves skin symptoms and quality of life in elderly psoriasis patients.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2474505"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}